Modern Active Surveillance in Prostate Cancer: A Narrative Review

Trent A. Pattenden, Dhanika Samaranayke, Andrew Morton, Wee Loon Ong, Declan G. Murphy, Elizabeth Pritchard, Susan Evans, Jeremy Millar, Venu Chalasani, Prem Rashid, Matthew Winter, Ian Vela, David Pryor, Stephen Mark, Nathan Lawrentschuk, Isaac A. Thangasamy

Research output: Contribution to journalReview ArticleOtherpeer-review

5 Citations (Scopus)


The use of PSA screening has led to downstaging and downgrading of prostate cancer at diagnosis, increasing detection of indolent disease. Active surveillance aims to reduce over-treatment by delaying or avoiding radical treatment and its associated morbidity. However, there is not a consensus on the selection criteria and monitoring schedules that should be used. This article aims to summarize the evidence supporting the safety of active surveillance, the current selection criteria recommended and in use, the incidence of active surveillance, barriers existing to its uptake and future developments in patient selection.

Original languageEnglish
Pages (from-to)115-123
Number of pages9
JournalClinical Genitourinary Cancer
Issue number1
Publication statusPublished - Feb 2023


  • Active surveillance
  • Intermediate risk prostate cancer
  • Low risk prostate cancer
  • MRI
  • Risk stratification

Cite this